{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:34:15Z","timestamp":1778538855124,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05295-9","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:43:36Z","timestamp":1741013016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An observational pilot study of an active surveillance tool to enhance pharmacovigilance in Brazil"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-5498","authenticated-orcid":false,"given":"Dhelio Batista","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-9985","authenticated-orcid":false,"given":"Marcus Vin\u00edcius Guimar\u00e3es","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6452-7977","authenticated-orcid":false,"given":"Pavandeep","family":"Bilkhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1977-8410","authenticated-orcid":false,"given":"Carolina","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1872-5278","authenticated-orcid":false,"given":"Ioana-Gabriela","family":"Fi\u0163a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3066-2406","authenticated-orcid":false,"given":"Felix","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1649-8133","authenticated-orcid":false,"given":"Si\u00f4n","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2050-898X","authenticated-orcid":false,"given":"Ana","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3789-7920","authenticated-orcid":false,"given":"Marcia","family":"Rangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-4891","authenticated-orcid":false,"given":"Katie","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7450-7719","authenticated-orcid":false,"given":"Alex","family":"Teckkam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8117-9185","authenticated-orcid":false,"given":"Roberto","family":"Zajdenverg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-7323","authenticated-orcid":false,"given":"Anup","family":"Pingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"5295_CR1","unstructured":"World Health Organization. Enhancing pharmacovigilance in low and middle income countries using smart safety surveillance. Geneva, WHO Pharmaceuticals Newsletter. 2018;2:26. https:\/\/iris.who.int\/bitstream\/handle\/10665\/272398\/WPN-2018-02-eng.pdf."},{"key":"5295_CR2","unstructured":"Bollyky TJ, Stergachis A. A report of the safety and surveillance working group. Bill & Melinda Gates Foundation, Seattle, USA. 2014; Final Report 11 19 13. https:\/\/docs.gatesfoundation.org\/documents\/SSWG%20Final%20Report%2011%2019%2013_designed.pdf."},{"key":"5295_CR3","unstructured":"World Health Organization. Safety of medicines: priming resource-limited countries for pharmacovigilance. WHO Drug Information. 2017;31:575\u201380. https:\/\/iris.who.int\/bitstream\/handle\/10665\/330944\/DI314-575-580-eng.pdf."},{"key":"5295_CR4","unstructured":"World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva, 2002; Report number: 9241590157. https:\/\/iris.who.int\/bitstream\/handle\/10665\/42493\/a75646.pdf."},{"key":"5295_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","volume":"36","author":"SN Pal","year":"2013","unstructured":"Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36:75\u201381.","journal-title":"Drug Saf"},{"key":"5295_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40264-016-0432-y","volume":"39","author":"M Mann","year":"2016","unstructured":"Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in Namibia: a cost-utility analysis. Drug Saf. 2016;39:859\u201372.","journal-title":"Drug Saf"},{"key":"5295_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/pds.4022","volume":"25","author":"M Mann","year":"2016","unstructured":"Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, et al. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia. Pharmacoepidemiol Drug Saf. 2016;25:1052\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5295_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12936-016-1410-7","volume":"15","author":"E Poirot","year":"2016","unstructured":"Poirot E, Soble A, Ntshalintshali N, Mwandemele A, Mkhonta N, Malambe C, et al. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. Malar J. 2016;15:384.","journal-title":"Malar J"},{"key":"5295_CR9","volume":"34","author":"DM Mota","year":"2018","unstructured":"Mota DM, Vigo A, Kuchenbecker RS. Evolution and key elements of the Brazilian pharmacovigilance system: a scoping review beginning with the creation of the Brazilian Health Regulatory Agency. Cad Saude Publica. 2018;34: e00000218.","journal-title":"Cad Saude Publica"},{"key":"5295_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40290-020-00349-6","volume":"34","author":"M Vogler","year":"2020","unstructured":"Vogler M, Ricci Conesa H, de Araujo FK, Moreira Cruz F, Simioni Gasparotto F, Fleck K, et al. Electronic reporting systems in pharmacovigilance: the implementation of VigiFlow in Brazil. Pharm Med. 2020;34:327\u201334.","journal-title":"Pharm Med"},{"key":"5295_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014828","volume":"98","author":"CJB Batista","year":"2019","unstructured":"Batista CJB, Correa RG, Evangelista LR, Fleck K, Silva L, Renaud F, et al. The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. Medicine. 2019;98: e14828.","journal-title":"Medicine"},{"key":"5295_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(24)00074-4","volume":"24","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Brito-Sousa JD, Murta F, Sampaio V, Balieiro P, et al. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study. Lancet Infect Dis. 2024;24:629\u201338.","journal-title":"Lancet Infect Dis"},{"key":"5295_CR13","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/S2214-109X(23)00542-9","volume":"12","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Murta F, Sampaio V, Balieiro P, Baia-Silva D, et al. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis. Lancet Glob Health. 2024;12:e467\u201377.","journal-title":"Lancet Glob Health"},{"key":"5295_CR14","unstructured":"GlaxoSmithKline. KRINTAFEL (tafenoquine)\u2014label. 2018;Reference ID: 4294835. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210795s000lbl.pdf."},{"key":"5295_CR15","unstructured":"Therapeutic Goods Administration: Australian public assessment report for tafenoquine (as succinate). Woden, AU: Australian Government - Department of Health; 2019. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-tafenoquine-succinate-190408.pdf."},{"key":"5295_CR16","unstructured":"Sociedade Brasileira de Medicina Tropical: Anvisa libera novo medicamento para tratar mal\u00e1ria. Bras\u00edlia, BR: SBMT; 2019. https:\/\/sbmt.org.br\/anvisa-libera-novo-medicamento-para-tratar-malaria\/?lang=en."},{"key":"5295_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2165\/00002018-200730100-00006","volume":"30","author":"K Johansson","year":"2007","unstructured":"Johansson K, Olsson S, Hellman B, Meyboom RH. An analysis of Vigimed, a global e-mail system for the exchange of pharmacovigilance information. Drug Saf. 2007;30:883\u20139.","journal-title":"Drug Saf"},{"key":"5295_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1365-3156.2004.01264.x","volume":"9","author":"F Perez","year":"2004","unstructured":"Perez F, Mukotekwa T, Miller A, Orne-Gliemann J, Glenshaw M, Chitsike I, et al. Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Trop Med Int Health. 2004;9:774\u201383.","journal-title":"Trop Med Int Health"},{"key":"5295_CR19","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/j.1365-3156.2005.01526.x","volume":"10","author":"M Manzi","year":"2005","unstructured":"Manzi M, Zachariah R, Teck R, Buhendwa L, Kazima J, Bakali E, et al. High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop Med Int Health. 2005;10:1242\u201350.","journal-title":"Trop Med Int Health"},{"key":"5295_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/09540121.2010.516348","volume":"23","author":"M Panditrao","year":"2011","unstructured":"Panditrao M, Darak S, Kulkarni V, Kulkarni S, Parchure R. Socio-demographic factors associated with loss to follow-up of HIV-infected women attending a private sector PMTCT program in Maharashtra. India AIDS Care. 2011;23:593\u2013600.","journal-title":"India AIDS Care"},{"key":"5295_CR21","doi-asserted-by":"publisher","first-page":"25606","DOI":"10.3402\/gha.v7.25606","volume":"7","author":"CS Hall","year":"2014","unstructured":"Hall CS, Fottrell E, Wilkinson S, Byass P. Assessing the impact of mHealth interventions in low- and middle-income countries\u2014what has been shown to work? Glob Health Action. 2014;7:25606.","journal-title":"Glob Health Action"},{"key":"5295_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5530\/jyp.2020.12.92","volume":"12","author":"JR Rabelo Melo","year":"2020","unstructured":"Rabelo Melo JR, Duarte EC, de Ara\u00fajo Ferreira K, Silveira Gon\u00e7alves Y, Vogler de Moraes M, Dourado Arrais PS. Under-reporting of adverse drug reactions among healthcare professionals in Brazil: an estimate based on national pharmacovigilance Survey. J Young Pharm. 2020;12:360\u20135.","journal-title":"J Young Pharm"},{"key":"5295_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5530\/jyp.2020.12.71","volume":"12","author":"JR Rabelo Melo","year":"2020","unstructured":"Rabelo Melo JR, Duarte EC, de Ara\u00fajo Ferreira K, Silveira Gon\u00e7alves Y, Vogler de Moraes M, Dourado Arrais PS. Assessment of knowledge, attitude, and practice of pharmacovigilance among healthcare professionals in Brazil. J Young Pharm. 2020;12:255\u201360.","journal-title":"J Young Pharm"},{"key":"5295_CR24","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0616-2022","volume":"56","author":"S Rodovalho","year":"2023","unstructured":"Rodovalho S, Dias ALB, Ade MP, Saint-Gerons DM, Castro JL, Beratarrechea A, et al. Acceptability of short message service (SMS) as a tool for malaria treatment adherence in the Brazilian Amazon: a qualitative study. Rev Soc Bras Med Trop. 2023;56: e06162022.","journal-title":"Rev Soc Bras Med Trop"},{"key":"5295_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12936-022-04047-3","volume":"21","author":"D Macias Saint-Gerons","year":"2022","unstructured":"Macias Saint-Gerons D, Rodovalho S, Barros Dias AL, Lacerda Ulysses de Carvalho A, Beratarrechea A, Monteiro WM, et al. Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth. Malar J. 2022;21:28.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05295-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:43:39Z","timestamp":1741013019000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05295-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5295"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05295-9","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participant consent was obtained at the clinics through the PVCs or the study website. All information for participants was available in English and Brazilian Portuguese on the Seta study website. The study was approved by the Brazilian Research Ethics Committee (CONEP), reference number CAAE\u201435245220.8.0000.0005.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dhelio Batista Pereira and Marcus Vin\u00edcius Guimar\u00e3es Lacerda received support from GSK for the conduct of the Seta study. Felix Jackson and Pavandeep Bilkhu are agency workers from medDigital Ltd contracted and paid by GSK to support the setup of the study, develop the Seta application, and write and review the study report. Carolina Duarte and Alex Teckkam were agency workers from medDigital Ltd during the time of the study. Felix Jackson also discloses being a major shareholder in medDigital Ltd. Marcia Rangel, Katie Rolfe, Si\u00f4n Jones, Ana Martin, Ioana-Gabriela Fi\u0163a, Anup Pingle, and Roberto Zajdenverg are employed by and hold financial equities in GSK. Roberto Zajdenverg also received support from GSK to participate in medical conferences as a GSK employee. The authors declare no other financial or non-financial relationships and activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}